A Safety and Tolerability Study of REGN88(SAR153191) in Subjects With Rheumatoid Arthritis

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 2008

Primary Completion Date

March 31, 2009

Study Completion Date

May 31, 2009

Conditions

Rheumatoid Arthritis

Interventions

DRUG

REGN88

Single dose of REGN88 and 43 day follow up.

OTHER

Placebo

Placebo to match REGN88 administration

Trial Locations (1)

Institute of Rheumatology under the Russian Academy of Medical Sciences, Moscow